Keyword: Purdue Pharma

Merrimack CEO becomes Yumanity chief; Lilly Bio-Medicines head leaves key launches behind; and 23andMe's drug leader exits for biotech board roles.

Ducharme rejoins Purdue at a time when it is trying to expand beyond the opioids that built but now threaten to sink its business.

The deal gives Eisai sole responsibility for global development and commercialization of a drug that is nearing FDA approval.

Purdue Pharma’s new R&D subsidiary, Imbrium Therapeutics, tapped TetraGenetics and its antibody discovery platform for non-opioid-based painkillers.

Alder hires Juno exec as CEO, Allergan brings in Abbott vet after investors demand change, and ResTORbio poaches Novartis researcher as clinical VP.

New clinical trial results of Eisai and Purdue's lemborexant suggest it could become a new force in the sleep disorder market, say the partners.

Former Ariad CEO leads Roivant and Arbutus' new RNA JV, Purdue Pharma names new R&D head, Immunomedics poaches AZ I-O exec as R&D chief.

Japanese pharma Eisai and traditional pain biopharma Purdue have posted positive late-stage results from their partnered sleep medication lemborexant.

Meyers retires as Gilead's commercial head, Kewalramani was promoted to Vertex's CMO, Recipharm CFO Stenqvist jumped ship to Sobi.

Struggling Teva bid farewell to longtime CFO Eyal Desheh, Immune Pharma's CEO Teper departed and Rgenix tapped ex-Novartis oncology scientist as CMO.